MedTrace Logo

An Open-Label Study to Evaluate Retreatment With LIPO-202

NCT02397525 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2015-08-13

No results posted yet for this study

Summary

Evaluate the safety of three 8-week courses of treatment with LIPO-202 in non-obese patients who have central abdominal bulging. Efficacy measurements will also be collected.

Conditions

  • Central Abdominal Bulging

Interventions

DRUG

LIPO-202

Sponsors & Collaborators

  • Neothetics, Inc

    lead INDUSTRY

Principal Investigators

  • Maria Feldman · Neothetics, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02397525 on ClinicalTrials.gov